Cargando…

The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors

We determined the impact of bone marrow fibrosis (BMF) on the clinical outcomes of newly diagnosed multiple myeloma (NDMM) patients in the current era of myeloma therapy. A total of 393 MM patients were included in the final analysis. The median followup was 83 months (range: 3.9 to 212 months). BMF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paul, Barry, Zhao, Yue, Loitsch, Gavin, Feinberg, Daniel, Mathews, Parker, Barak, Ian, Dupuis, Megan, Li, Zhiguo, Rein, Lindsay, Wang, Endi, Kang, Yubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433821/ https://www.ncbi.nlm.nih.gov/pubmed/32628819 http://dx.doi.org/10.1002/cam4.3265

Ejemplares similares

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients
por: Byun, Ja Min, et al.
Publicado: (2018)

Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo
por: Tandon, Vasudha, et al.
Publicado: (2022)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
por: Matsushita, Maiko, et al.
Publicado: (2023)

ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma
por: Jiang, Jifeng, et al.
Publicado: (2020)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2023)

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation
por: Sundaramoorthy, Pasupathi, et al.
Publicado: (2018)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
por: Yalnız, Fevzi Fırat, et al.
Publicado: (2017)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients
por: Bao, Li, et al.
Publicado: (2020)

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
por: Clemens, Pamela L., et al.
Publicado: (2016)

ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1
por: Balmanno, Kathryn, et al.
Publicado: (2023)

STEAP1 facilitates metastasis and epithelial–mesenchymal transition of lung adenocarcinoma via the JAK2/STAT3 signaling pathway
por: Huo, Shu-fen, et al.
Publicado: (2020)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma
por: Wu, Jian, et al.
Publicado: (2022)

RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect
por: Wu, Jian, et al.
Publicado: (2023)

Jak2-mediated phosphorylation of Atoh1 is critical for medulloblastoma growth
por: Klisch, Tiemo J, et al.
Publicado: (2017)

Epstein–Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma
por: Xia, Bing, et al.
Publicado: (2019)

Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
por: Gu, Jingli, et al.
Publicado: (2021)

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
por: Yousef, S, et al.
Publicado: (2015)

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
por: Hong, Andrew L, et al.
Publicado: (2019)

Hypoxia-induced proteasomal degradation of DBC1 by SIAH2 in breast cancer progression
por: Liu, Qiangqiang, et al.
Publicado: (2022)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
por: Patel, Urmeel H., et al.
Publicado: (2015)

Adherence to immunomodulatory drugs in patients with multiple myeloma
por: Cransac, Amélie, et al.
Publicado: (2019)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

TM-233, a novel analog of 1′-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities
por: Sagawa, Morihiko, et al.
Publicado: (2015)

Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma
por: Xu, Limei, et al.
Publicado: (2021)

Non-invasive detection of corneal sub-basal nerve plexus changes in multiple myeloma patients by confocal laser scanning microscopy
por: Koschmieder, Anita, et al.
Publicado: (2020)

The long non-coding RNA LINC00473 contributes to cell proliferation via JAK-STAT3 signaling pathway by regulating miR-195-5p/SEPT2 axis in prostate cancer
por: Xing, Zengshu, et al.
Publicado: (2020)

Studies on the changes of uPA system in a co-culture model of bone marrow stromal cells–leukemia cells
por: Zhou, Lanxia, et al.
Publicado: (2020)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Quantitative Phosphoproteomics of Proteasome Inhibition in Multiple Myeloma Cells
por: Ge, Feng, et al.
Publicado: (2010)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_djt3h1nd931q90tq92puj3aliq